Clinical Trial Update: Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing chemotherapy with lapatinib versus trastuzumab in HER2-positive metastatic breast cancer has completed; results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)
• Tykerb (lapatinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Breast Cancer | Phase 3 | Status: COMPLETED | Results posted: 2014-06-18